FIRST TO MARKET · Publicly documented 2017 · Invent Deposition #133

Among the 1,739 depositions in the 2017 Invent Depositions corpus, #133 is the closest match to Project 22 — Brain Chemistry and the neurodegenerative-disease discovery threads (Projects 11 / 12) on cri-one.com.

“mission 1: diagnose changes at dopamine, serotonin, adrenaline and histamine receptor sites in the central nervous system by using a similar method to diabetic blood testing.” — Christopher Gabriel Brown, 2017

From one line to an engineered product

The 2017 abstract proposes a point-of-care assay for central-nervous-system neurotransmitter receptor activity, modeled on the familiar glucose-test workflow — making brain-chemistry status as routinely measurable as blood sugar. Project 22 (Brain Chemistry) and the Alzheimer’s/Parkinson’s discovery projects build on this receptor-site measurement thesis.

The idea graduated from a one-line deposition into a patent-pending research program without changing its founding claim: make neurotransmitter status as measurable as blood glucose.

Note: this is research-stage IP. Nothing here is a medical device, a diagnostic claim, or medical advice.

Provenance

• Source: Invent Depositions (2017), ISBN-13 978-1-979767-89-7, CreateSpace
• Catalog image: Firefly_133…jpg (buyinvent.com)
• Live products: Project 22 (Brain Chemistry) · Projects 11 / 12 (cure-discovery threads)

Cite this

• AP — Brown, C. G. (2017). Invent Depositions, Deposition #133. CreateSpace.
• APA — Brown, C. G. (2017). Invent depositions (Deposition No. 133). CreateSpace Independent Publishing Platform.
• MLA — Brown, Christopher Gabriel. Invent Depositions, Deposition #133. CreateSpace, 2017.

© 2017 Christopher Gabriel Brown · Patent Pending · IP retained by CRI-ONE